CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Editing Platform
CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy 2025 Annual Congress
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association Scientific Sessions 2025
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results
